Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France - Full Text View

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00681369

Purpose

the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile

Condition
Breast Cancer

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

Drug Information available for: Ici 182780

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Retrospective
Official Title:	Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Evaluate Faslodex therapeutic strategy and treatment duration [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]
Describe the characteristics of patients treated with Faslodex [ Time Frame: At the end of the study ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	217
Study Start Date:	May 2007
Study Completion Date:	June 2007

Groups/Cohorts
1 Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007

Eligibility

Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Study Population

Hospital sample

Criteria

Inclusion Criteria:

Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00681369

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:

Alain FLINOIS

TNS Healthcare - France138, avenue Marx Dormoy92120 Montrouge

More Information

Responsible Party:	AstraZeneca ( Francisco Sapunar - Medical Science Director )
Study ID Numbers:	NIS-OFR-FAS-2007/1
Study First Received:	May 20, 2008
Last Updated:	May 20, 2008
ClinicalTrials.gov Identifier:	NCT00681369
Health Authority:	France: Haute Autorité de Santé Transparency Commission

Keywords provided by AstraZeneca:

breast cancer
fulvestrant
longitudinal study
France

Study placed in the following topic categories:

Skin Diseases
Fulvestrant
Breast Neoplasms
Breast Diseases

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009